440 results
Second generation biolimus drug-coated balloon in clinical practice
15 May 2024 – From EuroPCR 2024
Discover the potential applications of the new biolimus-coated balloon in treating de novo large vessel lesions, explore its effectiveness in addressing ISR based on findings from the BIO ASCEND ISR study, and uncover insights into the safety and feasibility of BA9 DCB in treating small vessel,...
Go beyond metal: exploring drug-eluting balloon technology in de-novo coronary lesions
15 May 2024 – From EuroPCR 2024
Through the study of two cases, this session examines the need for stenting bifurcation lesions and the role of DEB technology in avoiding stent-related complications in long diffuse disease. It emphasizes the benefits of SELUTION SLR balloons for de novo lesions, discussing how sustained limus release...
Tools and technologies guiding decision making in bifurcation PCI
15 May 2024 – From EuroPCR 2024
In this session, discover that provisional stenting in routine non-LM bifurcation using Resolute Onyx DES yields good mid-term outcomes without side branch intervention, provided the stent is sized to the distal reference and the side branch remains patent after a systematic POT. Learn how bifurcation stenting...
How do I confidently expand my DCB practice?
15 May 2024 – From EuroPCR 2024
This session offers insights on identifying appropriate lesions for DCB treatment, understanding the essential concepts for achieving optimal immediate results with DCB PCI, and exploring the long-term angiographic and clinical outcomes. The session emphasizes the importance of lesion preparation, notes that there are no contraindications for...
Expanding the indications of DCB for complex PCI scenarios
14 May 2024 – From EuroPCR 2024
This session, with the collaboration of various national societies, explores the use of drug-coated balloons (DCBs) in complex PCI scenarios, such as multivessel disease, left main, bifurcations, CTOs, or myocardial infarction. It includes case presentations and discussions on the procedural techniques, patient selection, and lesion preparation...
Hotline: advances in coronary physiology
14 May 2024 – From EuroPCR 2024
This hotline session explores the latest advancements in coronary physiology and their implications for percutaneous coronary intervention (PCI). Topics covered include the influence of pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI, the prognostic value of myocardial ischemic burden in STEMI...
Hotline: new coronary devices (DES, BRS, DCB)
14 May 2024 – From EuroPCR 2024
This hotline session provides a comprehensive overview of the latest clinical data on new coronary devices, including bioresorbable scaffolds, drug-coated balloons, and drug-eluting stents. Participants will learn about the outcomes of various randomized trials and registry studies, examining the performance of these innovative technologies in different...
PCI: complex procedures
14 May 2024 – From EuroPCR 2024
This session explores a series of complex PCI cases, including the management of left main stent restenosis after the chimney technique, aortic root dissection during right coronary artery PCI, treatment of very old saphenous graft disease, complex in-stent restenosis, and the management of persistent coronary fistula....
Left main and complex bifurcation stenting
14 May 2024 – From EuroPCR 2024
Watch this session focused on a patient with distal left main stenosis to understand that the stepwise provisional side branch (SB) stenting strategy is the standard approach for most left main trifurcation lesions. Discover the importance of optical frequency domain imaging for strategy determination and bifurcation...
Supraflex Cruz - Improving patient outcomes: from simple to complex patients
14 May 2024 – From EuroPCR 2024
Discover the remarkable performance of Supraflex Cruz in real-world clinical settings, showcasing exceptionally low event rates and demonstrating its safety and efficacy across a spectrum of high-risk patients, including the elderly and those with high bleeding risks, and delve into the ongoing TALENT and TUDEXO II...
